

flat nasal bridge with a small snub nose, but the overall pattern of the face does not seem to fit Robinow syndrome as I have seen it in a total of seven cases.

First, the frontal bossing is not impressive and actually looks more like a metopic ridge. Infants with Robinow syndrome usually have pronounced frontal bossing and more obvious macrocephaly than case 1 of Sabry *et al.* Her head also may seem large as a result of the obvious dystrophic condition she is in.

Second, the lower face is too fine and the chin too pointed for Robinow syndrome. The mouth does not look like the typical thin lipped "carp mouth". The overall facial structure seems too finely sculpted to me. The face in Robinow syndrome tends to be rather coarse, Greig hypertelorism-like, in contrast, with a rounded lower half. The coarseness can be so pronounced that sometimes metabolic investigations are initiated because a mucopolysaccharidosis is suspected (own observation).

Third, eyelid hypoplasia giving the impression of exophthalmos seems to be quite a constant feature. I do not see it in this patient.

Fourth, the mesomelia in case 1 is certainly not impressive. It is a highly variable feature and actually not of much use in the diagnosis (see, for instance, Bain *et al.*), but if present it is an extra argument for the diagnosis, so some measurements of bone length would have been helpful here.

Finally, stating that the labia minora and clitoris were "slightly hypoplastic" seems a bit vague. What is "slightly"? A photograph would have been helpful.

The photograph of subject 2 in fig 7 poses some difficulties. Though it is true that the facial abnormalities tend to become somewhat less obvious with age, some anomalies remain quite obvious: the snub nose, the hypertelorism, and the thick alveolar ridges. The face also remains rather square and coarse. Subject 2 has a large nose compared to some of my patients of the same age and his hypertelorism is rather modest. His face seems too fine, much like his sister's. His alveolar ridges can, of course, not be judged from the picture. In my opinion, a diagnosis of Robinow syndrome is not certain in his case either.

As far as case 2 is concerned, her photograph (fig 8) is more convincing. Particularly when comparing the lower half of her face with that of case 1, it will be seen that there is a clear difference between the two. In my opinion the face of case 2 is definitely more "Greig-like". Though there is no mesomelia in this patient, this feature can be variable, as stated. I feel that in this case the diagnosis of Robinow syndrome is probably correct. This patient is not related to the other patients and, considering this, I think it is possible that the authors have in fact encountered, in case 1 and subject 2, a new recessive malformation syndrome with some resemblance to Robinow syndrome.

MAURICE VAN STEENSEL

Department of Human Genetics, Clinical Genetics Section, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands

1 Sabry MA, Ismail EAR, Al-Naggar RL, *et al.* Unusual traits associated with Robinow syndrome. *J Med Genet* 1997;34:736-40.

2 Bain MD, Winter EM, Burn J. Robinow syndrome without mesomelic "brachymelia": a report of five cases. *J Med Genet* 1986;23:350-4.

This letter was shown to Dr Sabry *et al.*, who reply as follows.

We read the comments of Dr van Steensel concerning our report of unusual traits associated with Robinow syndrome. In family 1 of our report, we described a female patient with many of the constant traits of Robinow syndrome, who showed other unusual traits in addition. We also observed variable expression of some of the traits of Robinow syndrome in healthy sibs/cousins of the proband in this consanguineous family. Like many syndromes for which no molecular/biochemical/cytogenetic markers have been identified, the diagnosis of Robinow syndrome remains solely dependent on the clinical phenotype of the patients. Naturally, this gives wide scope for different subjective views to argue for or against a given diagnosis. This is particularly true for Robinow syndrome with its wide spectrum of inter/intrafamilial phenotypic heterogeneity that would be expected to reflect a corresponding degree of molecular variability. Of course the profile in the proband of family 1 does not show a straightforward Robinow phenotype, or it would have been of little interest to the genetics community. Although we bear in mind the possibility of a new Robinow-like malformation syndrome in family 1 of the report, we are reluctant to designate it a new syndrome until all available possibilities are exhausted. Incidentally, we have recently received a letter from Dr H G Brunner from the Department of Genetics, University Hospital, Nijmegen, expressing interest in our Robinow syndrome cases and requesting our collaboration in their ongoing molecular study to map and clone the gene(s) responsible, which we are now considering.

M A SABRY
E A R ISMAIL
N AL-TORKI
S FARAH

Kuwait Medical Genetics Centre, Farwania and IbnSina Hospitals, Kuwait

BOOK REVIEW

If you wish to order or require further information regarding the titles reviewed here, please write to or telephone the BMJ Bookshop, PO Box 295, London WC1H 9JR. Tel 0171 383 6244. Fax 0171 383 6662. Books are supplied post free in the UK and for BFPO addresses. Overseas customers should add 15% for postage and packing. Payment can be made by cheque in sterling drawn on a UK bank or by credit card (Mastercard, Visa, or American Express) stating card number, expiry date, and full name. (The price and availability are occasionally subject to revision by the Publishers.)

Human Cytogenetic Cancer Markers. Editors Sandra R Wolman, Stewart Sell. (\$125.00.) New Jersey, USA: Humana Press. 1997. ISBN 0-896-03357-0.

This book reviews the genetic changes observed in solid tumours with particular emphasis on the practical issues of diagnosis, prognosis, and monitoring therapy. The book provides comprehensive coverage of the impact of the new genetic technology in fur-

thering the understanding of the mechanisms underlying tumour development. The opening chapter illustrates the increasing relevance of genetic markers in tumour diagnosis and prognosis and provides a good introduction to the subject. Part 1 of the book, consisting of several chapters, covers the application of the major techniques, including flow cytometry, in situ hybridisation, CGH, and nucleic acid amplification. The relevance and applications of these techniques are well described. Part 2 of the book comprises comprehensive reviews of the current knowledge of the cytogenetic and molecular genetic changes observed in organ specific tumour types/subtypes. Each of these chapters is contributed by acknowledged experts in the field.

There is, almost inevitably, some variability in the apparent quality of the reviews and as advances in this field are taking place continually a book of this nature is always going to be a little behind hand. With the exception of an excellent chapter on the morphological, antibody, and chromosomal classification of haematological malignancies, this book does not cover leukaemias and lymphomas. One chapter at the very end of the book describes special techniques in cytogenetics, with emphasis on microdissection, which would perhaps have been better placed earlier in the volume along with the other methodologies. Although the colour plates are replicated as black and white photographs within the chapters, their placement within the centre of the book is disappointing. This necessitates frequent page turning, as the colour is fundamental to the illustration in some instances! However, this book provides excellent background information and an overview from which it would be possible to delve deeper using the cited references, although a quick scan for the new publications would also be wise in some instances.

A certain level of knowledge of solid tumours, cytogenetics, and molecular biology is assumed. This should be a useful book for the interested pathologist and clinician as well as students in these areas. Those in research will find the book an easy introduction to a topic and useful in the process of formulating ideas and methodological approaches before embarking on conducting their own investigations. Selected areas of cancer cytogenetics represented in this book are also areas of expanding interest for cytogeneticists and genetic technologists who, working in league with pathologists, may ultimately be able to provide more information of practical use for patients.

LIONEL WILLATT

JANET SHIPLEY

NOTICE

Call for patients with familial pancreatic disease: the EUROPAC Register

We are establishing a European register (EUROPAC) of families with hereditary pancreatitis, familial pancreatic cancer, and where pancreatic cancer has occurred as part of a familial cancer syndrome. This collabo-

ration in Liverpool is between the Department of Clinical Genetics (Dr Ian Ellis) and the Academic Department of Surgery (Professor John Neoptolemos). The data and samples are collected on behalf of ESPAC (The European Study Group for Pancreatic Cancer), Professor Markus Büchler, Berne, and Professor Hans Beger, Ulm. The study will collaborate with Dr David Whitcomb of the Midwest Multicenter Pancreatitis study group in the United States. We aim to recruit families who are prepared to donate blood samples for DNA studies. We hope to gain a clearer understanding of the genetic relationship between hereditary pancreatitis and familial pancreatic cancer, and develop screening protocols for at risk people.

Hereditary pancreatitis is associated with mutations in the recently identified cationic trypsinogen gene on 7q35, with a common

exon 3 point mutation (Arg¹¹⁷→His). There is a 30% risk of developing pancreatic cancer in those with hereditary pancreatitis. We plan to screen families for cationic trypsinogen gene mutations, and for cancer susceptibility genes depending on the family history. In addition, analysis of tumour tissue will enable us to identify regions of loss of heterozygosity (LOH), with the subsequent potential for linkage studies, identification of tumour suppressor genes involved in pancreatic malignancies, and very early markers of tumourigenesis. Screening of at risk people by analysis of cells from pancreatic fluid may then become viable.

The criteria for inclusion in the study are as follows.

Hereditary pancreatitis. Three relatives with chronic pancreatitis in the absence of

ethanol dependence, hypercalcaemia, or obstructive cause.

Familial pancreatic cancer. Two first degree relatives with pancreatic ductal adenocarcinoma. Three or more relatives with pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma in any two relatives where the sum of their ages is less than 110 years.

Other familial cancer syndromes. A single documented pancreatic ductal adenocarcinoma in any family with an established familial cancer syndrome, for example, BRCA2, FAMMM, A-T, HNPCC, or FAP.

If you know of any suitable families who may be interested in joining the study, please contact Fiona McDonald at Clinical Genetics, Alder Hey Children's Hospital, Eaton Road, Liverpool L12 2AP, UK, or on 0151 252 5905.

Notice to contributors

The *Journal of Medical Genetics* publishes original research relevant to medical genetics, along with reviews, annotations, and editorials on important and topical subjects. It also acts as a forum for discussion, debate, and information exchange through its Letters to the Editor column, conference reports, and notices. The journal particularly encourages submissions on the molecular basis of human disease, the clinical manifestations of genetic disorders, applications of molecular genetics to medical practice, and the systematic evaluation of such applications. The journal attempts to handle the review process and publication as expeditiously as possible. Accelerated publication is available where warranted by scientific urgency and recommended by reviewers. Submissions are accepted only on the understanding that they have not been and will not be published elsewhere, and are subject to editorial revision. They should be sent to:

Professor Martin Bobrow
Editor, Journal of Medical Genetics
Department of Medical Genetics
Box 238, Level 3, Laboratories Block
Addenbrooke's Hospital
Cambridge CB2 2QQ, UK
Tel: +44 (0)1223 331190
Fax: +44 (0)1223 331206
e-mail 101573.2243@compuserve.com

Manuscripts from North America may be sent directly to the North American Editor. Manuscripts that do not conform to the following instructions may be returned for modification before being reviewed.

- **All submissions** must be typewritten on one side of the paper only, using double spacing and ample margins. A total of three copies of articles and letters should be supplied, together with three copies of any tables or figures. The pages should be numbered. All abbreviations must be defined.
- Manuscripts must be accompanied by:
 - **Covering Letter** Each author must sign the covering letter as evidence of consent to publication and all authors will be required to transfer copyright of their articles to the journal before publication.
 - **Consent** All identifiable photographs of patients should be accompanied by written permission for use. Pedigrees, particularly those containing information on people who may be presymptomatic carriers of later onset disease, should, as far as possible, be anonymised.
 - **Ethical approval** The critical assessment of submitted papers will include ethical considerations; documentary evidence (where relevant) of ethical committee review and approval will be very helpful.
 - **Title sheet** stating the title of the paper, as well as a short title, the authors, their departments and institutions, and the name and postal address (+ Tel/Fax numbers) of the corresponding author.
 - **Referees** Authors are welcome to suggest people particularly competent to act as referees; although the journal may not use the suggested referees on that occasion, they will be added to our database. Conversely, authors' wishes on those whom they would prefer not to referee their work will be respected.

Categories of contributions

- 1. Original papers** represent a substantial body of laboratory or clinical work. The study should be presented in sections, namely:
 - **Abstract** No more than 250 words, summarising the problem being considered in the study, how the study was performed, the salient results and the principal conclusions of the study. *Structured abstracts* (in the format used by eg the *British Medical Journal* and the *Journal of the American Medical Association*) have been shown to be more useful to readers, and their use is encouraged wherever possible.
 - **Keywords** (maximum of four) These should be given beneath the abstract.
 - **Introduction** Brief description of the background that led to the study.
 - **Methods** Details relevant to the conduct of the study. Statistical methods should be clearly explained at the end of this section.
 - **Results** Work should be reported in SI units. Undue repetition in text and tables should be avoided. Comment on validity and significance of results is appropriate but broader discussion of their implications should be placed in the next section.
 - **Discussion** The nature and findings of the study are placed in context of other relevant, published data. Subheadings that aid clarity of presentation are encouraged.
 - **Data access** Reference should be made to availability of detailed data, either through public databases or otherwise, and to availability of materials used for reported investigations. It is generally expected that

genomic and similar data should be lodged in appropriate public databases at or before the time of publication. Authors are encouraged to make DNA or cell lines available to other workers.

- **Acknowledgments and affiliations** People with direct involvement in the study but not included in authorship may be acknowledged. The source of financial support and industry affiliations of all those involved should be stated.
- **References** In accordance with the Vancouver agreement these are cited by the numerical system and listed in the order cited in the text, not in alphabetical order by authors' names. (In the text, the reference number should be given between square brackets on the line, not superscript.) All authors should be listed. Journal titles are abbreviated in accordance with the style of *Index Medicus*. See references in the journal.
- **Figures** should be kept to a minimum and should be numbered consecutively in Arabic numerals. Legends should be typed on a separate sheet.
- **Tables** should not be included in the body of the text but should be typed on separate pages and numbered with Arabic numerals. A legend should be provided above the table.
- **Illustrations** Colour illustrations can be accepted; however, authors are asked to pay part of the cost.
- **Nomenclature** Current standard international nomenclature should be adhered to.
 - Chromosomes:** *ISCN 1995. An International System for Human Cytogenetic Nomenclature*, Mitelman F (ed); S Karger, Basel, 1995
 - Genes:** **McAlpine P. In: The Genetics Nomenclature Guide (Human).** *Trends in Genetics Supplement*, March 1995. For latest references, instructions, and list of approved symbols see URL <http://www.gene.ucl.ac.uk/nomenclature/> (or contact nome@galton.ucl.ac.uk)
 - Enzymes:** Enzyme nomenclature: recommendations of the nomenclature committee of the International Union of Biochemistry. New York: Academic Press, 1992 Information also available on URL <http://expasy.hcuge.ch/sprot/enzyme.html>

2. Short reports

A brief communication presenting laboratory or clinical work, collected case reports, or single case reports. Reports of single mutations at loci which have already been documented will be published only if they are of unusual clinical or biological interest. The format can be identical to Original papers (see above) but in many circumstances the main body of the text may be better presented without division into sections. Short reports are intended to occupy no more than 2 printed pages; equivalent to about 1000 words, 2 tables/figures, and about 15 references. Brevity and clarity are always likely to enhance the chance of a manuscript being accepted for publication.

3. Review articles

Authors are welcome to discuss possible topics for review directly with the Editor.

4. Syndrome of the month

These reviews are commissioned by special editors, to whom suggestions can be addressed.

5. Hypothesis articles

Contributions which present an interesting theory, discussed in relation to published data, are welcome.

6. Diagnostic advances

A limited number of brief notes, occupying no more than one printed page, with novel technical information whose dissemination is likely to be of importance to those involved in running clinical and laboratory genetic services.

7. Letters

These are welcome on any relevant topic and will be published rapidly. Those relating to or responding to previously published items in the journal will be shown to those authors, where appropriate.

Proofs

One page proof will be sent to the author submitting the paper and alterations on the proof, apart from printer's errors, are not permitted. Reprints may be ordered when the proof is returned.

Disk version Manuscripts are published directly from disk. Final revised versions of papers will therefore be needed as hard copy and on disk. Instructions will be sent to authors on invitation to revise or on acceptance.

A complimentary copy of the journal will be sent to the corresponding author on publication.